FTD-GRN

Clinical trials for FTD-GRN explained in plain language.

Never miss a new study

Get alerted when new FTD-GRN trials appear

Sign up with your email to follow new studies for FTD-GRN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

One-Shot gene therapy could slow genetic dementia – first human trial underway

Disease control Recruiting now

This study tests a new gene therapy called AVB-101 for people with a genetic form of frontotemporal dementia (FTD-GRN). The treatment is given once, directly into the brain, to restore a missing protein and potentially slow or stop the disease. About 18 adults aged 30-75 with ear…

Matched conditions: FTD-GRN

Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control

Last updated May 15, 2026 11:56 UTC

FTD-GRN

Get alerted when new FTD-GRN trials appear

One-Shot gene therapy could slow genetic dementia – first human trial underway